Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

448 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparative analysis of breast cancer recurrence risk for patients receiving or not receiving adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF). Data supporting the occurrence of 'cures'.
Demicheli R, Miceli R, Brambilla C, Ferrari L, Moliterni A, Zambetti M, Valagussa P, Bonadonna G. Demicheli R, et al. Among authors: miceli r. Breast Cancer Res Treat. 1999 Feb;53(3):209-15. doi: 10.1023/a:1006134702484. Breast Cancer Res Treat. 1999. PMID: 10369067
Biological and clinical evaluation of lanreotide (BIM 23014), a somatostatin analogue, in the treatment of advanced breast cancer. A pilot study by the I.T.M.O. Group. Italian Trials in Medical Oncology.
Di Leo A, Ferrari L, Bajetta E, Bartoli C, Vicario G, Moglia D, Miceli R, Callegari M, Bono A. Di Leo A, et al. Among authors: miceli r. Breast Cancer Res Treat. 1995 Jun;34(3):237-44. doi: 10.1007/BF00689715. Breast Cancer Res Treat. 1995. PMID: 7579488 Clinical Trial.
The aromatase inhibitor letrozole in advanced breast cancer: effects on serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels.
Bajetta E, Ferrari L, Celio L, Mariani L, Miceli R, Di Leo A, Zilembo N, Buzzoni R, Spagnoli I, Martinetti A, Bichisao E, Seregni E. Bajetta E, et al. Among authors: miceli r. J Steroid Biochem Mol Biol. 1997 Nov-Dec;63(4-6):261-7. doi: 10.1016/s0960-0760(97)00120-9. J Steroid Biochem Mol Biol. 1997. PMID: 9459192 Clinical Trial.
Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
Gasparini G, Toi M, Miceli R, Vermeulen PB, Dittadi R, Biganzoli E, Morabito A, Fanelli M, Gatti C, Suzuki H, Tominaga T, Dirix LY, Gion M. Gasparini G, et al. Among authors: miceli r. Cancer J Sci Am. 1999 Mar-Apr;5(2):101-11. Cancer J Sci Am. 1999. PMID: 10198732 Clinical Trial.
Re: Dormancy of mammary carcinoma after mastectomy.
Demicheli R, Miceli R, Valagussa P, Bonadonna G. Demicheli R, et al. Among authors: miceli r. J Natl Cancer Inst. 2000 Feb 16;92(4):347-8. doi: 10.1093/jnci/92.4.347. J Natl Cancer Inst. 2000. PMID: 10675389 No abstract available.
The luteinising hormone-releasing hormone analogue triptorelin with or without the aromatase inhibitor formestane in premenopausal breast cancer: effects on bone metabolism markers.
Martinetti A, Ferrari L, Celio L, Mariani L, Miceli R, Zilembo N, Di Bartolomeo M, Toffolatti L, Pozzi P, Seregni E, Bombardieri E, Bajetta E. Martinetti A, et al. Among authors: miceli r. J Steroid Biochem Mol Biol. 2000 Dec 1;75(1):65-73. doi: 10.1016/s0960-0760(00)00138-2. J Steroid Biochem Mol Biol. 2000. PMID: 11179910 Clinical Trial.
448 results